

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Emini, Emilio A. et al.

Serial No. 10/645,883

Filed: August 21, 2003

For: ADENOVIRUS SEROTYPE 24 VECTORS, NUCLEIC
ACIDS AND VIRUS PRODUCED THEREBYArt Unit: 1644

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By _____

Date May 5, 2005



INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Anna L. Cocuzzo

Attorney _____ For Applicant(s)

Reg. No. 42,452

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 1273

Date: May 5, 2005

(use as many sheets as necessary)


DISCLOSURE
OIP E 5161
APPLICANT
MAY 09 2005
PARENT & TRADEMARK OFFICE
(if necessary)

Application Number	10/645,883
Filing Date	August 21, 2003
First Named Inventor	Emini, Emilio A. et al.
Group Art Unit	1644
Examiner Name	

Sheet	1	of	2	Attorney Docket Number	21366
-------	---	----	---	------------------------	-------

[illegible][illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2004

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use many sheets as necessary)		COMPLETE IF KNOWN	
		Application Number	10/645,883
		Filing Date	August 21, 2003
		First Named Inventor	Emini, Emilio A. et al.
		Group Art Unit	1644
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	21366

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Mizuguchi, H. et al. "Approaches for generating recombinant adenovirus vectors", Advanced Drug Delivery Reviews", 2001, Vol. 52, pp. 165-176
		Harris, J. et al. "Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE", Human Molecular Genetics, 2002, Vol. 11, pp. 43-58
		Shiver, J. et al. "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 2002, Vol. 415, pp. 331-335
		Fitzgerald, J. et al. "A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag", The Journal of Immunology, 2003, Vol. 170, pp. 1416-1422
		Patterson, L. et al. "Potent, Persistent Cellular Immune Responses Elicited by Sequential Immunization of Rhesus Macaques with Ad5 Host Range Mutant Recombinants Encoding SIV Rev and SIV Nef", DNA and Cell Biology, 2002, Vol. 21, pp. 627-635
		Walker, B. et al. "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals", Science, 1988, Vol. 240, pp. 64-66
		Messmer, D. et al. "Human Immunodeficiency Virus Type 1 Nef Mediates Activation of STAT3 in Immature Dendritic Cells", AIDS Research and Human Retroviruses, 2002, Vol. 18, pp. 1043-1050
		Hosmalin, A. et al. "An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes", Proc. Natl. Acad. Sci. USA, 1990, Vol. 87, pp. 2344-2348

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003